Incyte Announces Abstracts Accepted for Presentation at the 2019 ASCO Annual Meeting and the 24th Congress of EHA
Incyte Corporation (Nasdaq:INCY) announces that multiple abstracts highlighting data from its oncology portfolio will be presented at the upcoming 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held from May 31-June 4, 2019, in Chicago, Illinois; and the 24th Congress of the European Hematology Association (EHA), to be held June 13-16, 2019, in Amsterdam, the Netherlands.
Abstracts accepted for presentation at ASCO feature genomic profiling data from Incyte’s ongoing Phase 2 FIGHT-202 trial evaluating its selective fibroblast growth factor receptor (FGFR) inhibitor, pemigatinib, in patients with cholangiocarcinoma, as well as efficacy and safety data from the Novartis-sponsored GEOMETRY mono-1 trial of capmatinib, the investigational selective MET inhibitor licensed to Novartis by Incyte. Additionally, data to be presented at EHA will showcase the continued study of Incyte’s JAK1/JAK2 inhibitor, ruxolitinib, in myeloproliferative neoplasms (MPNs).
"Our presence at ASCO and EHA illustrates Incyte’s ongoing commitment to discovering and developing therapeutic options that address significant unmet medical needs for patients,” said Steven Stein, M.D., Chief Medical Officer, Incyte. “We are pleased to highlight new data on two investigational medicines – pemigatinib and capmatinib – that were discovered by Incyte scientists and for which we anticipate applications for initial U.S. regulatory approvals later this year, as well as data that furthers our understanding of the treatment of MPNs.”
Key ASCO and EHA abstracts include:
Capmatinib (INC280) in METΔex14-mutated advanced non-small cell lung cancer (NSCLC): efficacy data from the phase 2 GEOMETRY mono-1 study (Abstract #9004, oral abstract session)
- Monday, June 3, 2019, 9:12 – 9:24 a.m. CT, Hall B1
Comprehensive genomic profiling in FIGHT-202 reveals the landscape of actionable alterations in advanced cholangiocarcinoma (Abstract #4080, poster session)
- Monday, June 3, 2019, 8:00 – 11:00 a.m. CT, Hall A
Impact of myeloproliferative neoplasms (MPNS) and perceptions of treatment goals amongst physicians and patients in 6 countries: an expansion of the MPN Landmark Survey (Abstract #PF681, poster presentation)
- Friday, June 14, 2019, 5:30 – 7:00 p.m. CEST, Poster area
Real-world safety data from a non-interventional long-term post authorization safety study of ruxolitinib in myelofibrosis (Abstract #PF679, poster presentation)
- Friday, June 14, 2019, 5:30 – 7:00 p.m. CEST, Poster area
Safety and efficacy of ruxolitinib (RUX) in patients with myelofibrosis (MF) and anemia (hemoglobin <10g/dL): Results at Week 24 of the REALISE trial (Abstract #PS1465, poster presentation)
- Saturday, June 15, 2019, 5:30 – 7:00 p.m. CEST, Poster area
Where the use of compounds described herein is either investigational or being studied for (a) new use(s), efficacy and safety have not been established, and there is no guarantee that such compounds will become commercially available for the use(s) under investigation.
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit the Company’s website at www.incyte.com.
Follow @Incyte on Twitter at https://twitter.com/Incyte.
Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the Company’s development pipeline and whether or when any development compounds will be approved for use in humans anywhere in the world, its presentation plans for the upcoming ASCO and EHA annual meetings and its goal of improving the lives of patients, contain predictions, estimates and other forward-looking statements. These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments and the risks related to the efficacy or safety of the Company’s development pipeline, the results of further research and development, the high degree of risk and uncertainty associated with drug development, clinical trials and regulatory approval processes, other market or economic factors and competitive and technological advances; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission, including its Form 10-Q for the quarter ending March 31, 2019. Incyte disclaims any intent or obligation to update these forward-looking statements.
+1 302 498 6171
Michael Booth, DPhil
+1 302 498 5914
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Delta-Q Technologies Announces Its New RQ350 Battery Charger for Electric Vehicles and Machines27.5.2020 23:51:00 EEST | Press release
Today, Delta-Q Technologies (Delta-Q) introduces its latest sealed charger with the RQ350 for electric vehicles and industrial machines. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200527005918/en/ The RQ350 is an expansion of Delta-Q's RQ Series offering OEMs a charging solution for lower power applications. (Photo: Business Wire) Having found significant market success with the IC Series chargers rated from 650 to 1200 watts, Delta-Q has set its sights on lower power applications with its new 350-watt charger. This new build was designed and tested to meet automotive levels of product reliability, improving machine runtimes. “The RQ350 is a response to our customers’ needs in multiple application segments,” says Lloyd Gomm, VP of Business Development. “Our customers have asked us to bring our high reliability charger design into both lower and higher capacity battery charging applications. The RQ350 solidly answers the
City of Austin Partners with NTT to Accelerate Smart City Technologies27.5.2020 23:00:00 EEST | Press release
The City of Austin and NTT Corporation (NTT) today announced their intention to partner on an Accelerate Smart pilot project that will use new technologies to analyze traffic patterns, ease congestion and support community planning in Austin. NTT’s Accelerate Smart data platform, as well as modular data center infrastructure for edge deployments, will monitor traffic-related issues downtown using Internet of Things (IoT) devices deployed at the intersections of Cesar Chavez Street and Trinity Street and Neches Street and 8th Street. The smart city project will collect traffic-related and mobility data through vehicle counting and classification, as well as wrong way vehicle occurrences, to provide real-time notifications and better inform how to implement appropriate solutions to fit traffic patterns. “We are piloting NTT because these solutions have the potential to help Austin digitally transform how people move safely through the city. By better understanding the data and causal eff
Monument Re Completes Acquisition of GreyCastle Holdings Ltd and Its Subsidiaries27.5.2020 20:54:00 EEST | Press release
Monument Re announced today that it has completed the acquisition of GreyCastle Holdings Ltd. (‘GreyCastle’) and its subsidiaries, which include GreyCastle Life Reinsurance (SAC) Ltd. and GreyCastle Services Ltd., following receipt of regulatory approval from the Bermuda Monetary Authority. About GreyCastle GreyCastle was founded in 2014 by a group of institutional investors to reinsure a block of XL Life Reinsurance life and annuity liabilities of approximately USD4bn. About Monument Re Monument Re Limited is a life Reinsurance and Insurance Holding Company with a presence in Bermuda, Ireland, Belgium, Luxembourg, the Netherlands and Guernsey, with branches in Spain, Italy, France and Germany. Monument Re operates as a reinsurer and acquirer of European asset intensive portfolios. Through this strategy, Monument Re assumes asset-based risks within its risk appetite and efficiently operates these businesses or portfolios. Monument Re is subject to Group Supervision by the Bermuda Monet
Morgan Stanley Sustainable Signals: Asset Owners See Sustainability as Core to Future of Investing27.5.2020 16:18:00 EEST | Press release
A majority of asset owners globally actively integrate ESG factors into their investment process, according to a new survey published today by the Morgan Stanley Institute for Sustainable Investing and Morgan Stanley Investment Management. The new survey polled 110 public and corporate pensions, endowments, foundations, sovereign wealth entities, insurance companies and other large asset owners worldwide, 92% of which had total assets over $1 billion. The survey gathered insights about trends, motivations, challenges and implementation approaches in sustainable investing. This work builds on the Institute’s extensive body of research tracking sustainable investing trends over the last six years through its Sustainable Signals survey series focused on individual investors, asset owners and asset managers. “These results provide an additional proof point that sustainable investing has become table stakes,” said Audrey Choi, Chief Sustainability Officer and CEO of the Institute for Sustai
Sisvel Announces the First Licensees of Its Video Coding Licensing Platform27.5.2020 16:00:00 EEST | Press release
Sisvel International S.A. (“Sisvel”) today announced that Mitsubishi Electric Corporation (“Mitsubishi Electric”) has entered into a patent license agreement for both Sisvel’s VP9 and AV1 Licensing Programs. “As a company with a long tradition in research and development in the video coding technologies, it goes without saying that we respect patent positions held by other innovators and that we take a license under the patents offered by Sisvel’s Video Coding Licensing Platform implemented in our products,” says Mr. Yoshimichi Shishido, Senior General manager of Corporate Licensing Division at Mitsubishi Electric. “We have the utmost respect for Mitsubishi Electric’s position and welcome them as the first licensee of our patent pools. We believe this represents a strong signal to the market and we expect that other respectful implementers will follow Mitsubishi Electric’s example,” says Mattia Fogliacco, President of Sisvel International S.A.. Likewise, Sisvel has also granted a licen
Rimini Street Speeds Software Issue Resolution by 23% with New Artificial Intelligence Applications27.5.2020 16:00:00 EEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that it has reduced software issue resolution times by 23% using its new patent pending Rimini Street Artificial Intelligence Support Applications (AI Applications), and that to date the AI Applications have won two awards for innovation and achievement in customer service. The new AI Applications are a result of Rimini Street’s continued investment in optimizing support processes and ensuring global service delivery outcomes at scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200527005073/en/ Rimini Street Speeds Software Issue Resolution by 23% with New Artificial Intelligence Applications (Graphic: Business Wire) Delivering a Better Client Experience Through Artificial Intelligence The Rimini Street A
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom